Drug Checking Services: A Harm Reduction Field Guide

Drug checking is the practice of testing a substance to learn what is actually in it. For buyers of MDMA, LSD, ketamine, and street psilocybin, drug checking is one of the few evidence-based tools available to reduce the real and well-documented harms of an unregulated drug supply. It is not a magic shield. It is a way to convert a blind purchase into a more-informed decision, and the difference between those two states, in harm-reduction terms, is the entire reason drug checking exists.

This guide covers what psychedelic drug checking services actually do, what the three main tools (reagent test kits, fentanyl test strips, and lab-level instruments like FTIR and Raman spectrometers) catch and miss, where each is legal today, how a person uses each one in practice, and the limits and critiques attached to the practice. The framing throughout is harm-reduction: drug checking is a way to make a bad situation less bad, not a way to make a bad situation safe.

Why Drug Checking Exists

The unregulated street drug supply has changed dramatically over the last decade. Public health reporting and harm-reduction research, much of it summarized in the peer-reviewed Harm Reduction Journal, has documented several trends that matter directly to buyers of MDMA, LSD, ketamine, and street psilocybin.

First, the supply is more adulterated than buyers assume. Adulterants include cutting agents like caffeine and lidocaine, substitutes with similar appearance but different effects, and in some markets, more dangerous contaminants including fentanyl and novel synthetic opioids. Second, the dose in a pressed pill or a bag of powder is unpredictable, and what looks like a single dose can be far more concentrated than expected. Third, the substances themselves have drifted: pills sold as MDMA increasingly contain substitutes like MDA, methylone, or synthetic cathinones; powders sold as psilocybin are sometimes entirely synthetic tryptamines or 4-AcO-DMT.

Drug checking emerged in this context as a way to give buyers real information about the substance they are about to use. It is structural: harm reduction organizations from the drugs-and-me harm reduction project to well-established European programs use similar tools and similar reasoning. The science is consistent. Drug checking does not eliminate risk. It shifts the buyer's information state from "no data" to "some data," and that shift has been measured to change behavior in measurable ways.

Reagent Test Kits: What They Catch and Miss

A reagent test kit is a small bottle of a chemical solution, called a reagent, that produces a visible color change when a small sample of a substance is added. The five most relevant reagents for psychedelic testing are Ehrlich's, Mecke, Mandelin, Liebermann, and Simon's. Each reagent is calibrated to react with a specific functional group, the molecular feature that defines a chemical family, so each reagent produces a different color with a different class of compounds. Ehrlich's turns purple in the presence of indoles, the family that includes LSD, psilocybin, DMT, and the tryptamines. Mecke distinguishes MDMA from MDA and related compounds. Simon's is the reliable test for MDMA and methamphetamine-style stimulants.

The right practice for psychedelic buyers is to run two or three reagents on the same sample, because a single reagent can produce false positives. A sample that turns dark purple with Ehrlich's but produces no color change with Mecke is more likely an indole-class compound (LSD, psilocybin) than an MDMA-family stimulant. A pressed pill that turns black with Mecke and blue with Simon's is consistent with MDMA. A pressed pill that turns dark quickly only with Mecke is consistent with MDA or another substitute. Cross-referencing reagents is the standard approach used by trained drug-checking operators and is the basis of the field guide used by DanceSafe and most harm-reduction programs.

What reagent kits do not do is just as important. Reagents do not quantify dose. A strong color change does not mean a strong pill, only that the target functional group is present. Reagents do not identify novel compounds or novel cathinones that have not been added to a reagent reference chart. Reagents cannot detect non-indole contaminants like fentanyl, which is why fentanyl test strips are used as a complementary tool. Reagents can produce false positives, especially in low-quality samples, and can be confounded by the presence of multiple compounds in a single sample.

Fentanyl Test Strips: How They Work

Fentanyl test strips use immunoassay chemistry, the same antibody-based detection used in at-home pregnancy tests and many clinical drug tests, to detect the presence of fentanyl and many of its close analogues in a dissolved sample. A small scraping of the substance under test is dissolved in a small amount of water. The strip is dipped into the water for about 15 seconds. The liquid travels up the strip. One line appearing (the control line) within about two minutes means the strip detected no fentanyl. Two lines means the test is either negative or the fentanyl concentration is below the detection threshold of the strip.

The detection threshold of a typical fentanyl test strip is around 1 to 5 micrograms per milliliter, depending on the brand and storage conditions, so the strip is calibrated for trace detection rather than dose quantification. This is the right calibration for the harm-reduction use case: a buyer does not need to know the exact quantity of fentanyl in a sample to be told the sample is unsafe to use.

The strips have real limitations. They do not catch every fentanyl analogue, and novel synthetic opioids are appearing in the drug supply faster than strip manufacturers can validate them. They do not detect non-opioid contaminants like xylazine or levamisole. They cannot distinguish between fentanyl and a similar-acting but different compound. They also produce false negatives when the dissolved sample is too dilute, when the fentanyl is encapsulated inside a binding filler, or when the strip has been stored improperly. None of these limitations is a reason to skip the strips. They are a reason to use them as a complement to a broader testing approach rather than as a stand-alone tool.

Lab-Level Testing: FTIR and Raman Spectroscopy

The gold standard in drug checking is lab-level testing using instruments like Fourier-transform infrared (FTIR) spectrometers and Raman spectrometers. Both instruments identify compounds by the way they absorb or scatter light: FTIR uses infrared light to measure the absorption pattern of a sample, and Raman uses light at a different wavelength to measure the inelastic scattering of photons off the molecules in a sample. Each compound has a unique spectrum that can be matched against a library of known spectra. Both are non-destructive: a small sample can be tested, the spectrum read, and the sample recovered (with care) for confirmation testing.

FTIR and Raman spectroscopy are widely used in pharmaceutical-quality control laboratories and in the harm-reduction field. Several harm-reduction services run mobile FTIR units at music festivals and in fixed harm-reduction centers in cities like Vancouver and Zurich. The instruments are practical for harm-reduction work because they can identify a wide range of compounds in a matter of minutes, including novel synthetic cathinones and novel synthetic opioids that reagent kits might miss. They also produce quantitative readings in some setups, giving buyers a much more complete picture than a reagent or strip can provide.

The practical limitation is access. FTIR and Raman instruments cost thousands to tens of thousands of dollars, and they require trained operators. Field-deployed drug-checking services that run them exist but are not at scale in most communities. For most buyers, the closest practical tool is a fixed harm-reduction center or a festival drug-checking service. The Harm Reduction International directory is one resource for finding such services. The instrument is the future of drug checking; for now, its reach is uneven.

Where Drug Checking Is Legal Today

Drug checking for personal use is explicitly legal in several European jurisdictions. The Netherlands has run government-supported drug-checking services since the early 1990s. Switzerland rolled out federal drug-checking coverage starting with the cities. Spain permits it at the regional level in several autonomous communities. The United Kingdom permits drug checking at festivals under specific licensing conditions. Germany added federal drug-checking protections in 2024.

Across the Atlantic, Canada permits drug checking at harm-reduction sites including the Insite supervised consumption site in Vancouver, which has run on-site drug-checking services since 2016. Several Australian states permit drug checking at music festivals and at fixed harm-reduction centers.

In the United States, drug checking for personal use sits in a complicated legal position. Decriminalization has spread through several cities and states, and the legal ambiguity around testing for personal use is the worst it has ever been. Fentanyl test strips are now explicitly legal in over half of US states for harm-reduction use. The Drug Enforcement Administration has historically treated possession of testing reagents as evidence of intent, but state-level protections have been spreading. Drug-checking services remain rare in the United States compared to Europe, but harm-reduction drug-checking programs have been growing in cities including New York, San Francisco, Boston, and Seattle.

For most buyers, the practical question is what advice applies regardless of where they live. A buyer in a region without a fixed drug-checking service can still access reagent kits and fentanyl test strips from harm-reduction mail-order services. The legal status in their specific jurisdiction is a separate question; the user's responsibility is to know it.

How to Use a Reagent Kit in Practice

The standard harm-reduction workflow for reagent kits is straightforward and worth following precisely. The first step is to acquire a kit from a reputable supplier. DanceSafe and Bunk Police are two well-known suppliers; their kits include color charts matched to specific compounds. The second step is to set up on a clean, dry, well-lit surface with the reagent bottle, the color chart, and a ceramic or glass plate. Paper or porous surfaces absorb the reagent and produce unreliable readings.

The third step is to obtain a small sample, on the order of a single grain of rice, for each substance. For pressed pills, the standard practice is to scrape a small amount off the crushed edge of the pill rather than the outer surface, which is often coated in dye and binders that interfere with the test. For powders, the standard practice is to use a clean tool to take a small sample from the interior of the bag rather than the surface. For blotter, a small piece of the blotter is tested alongside a small piece of plain blotter as a control.

The fourth step is to apply a single drop of reagent and observe the color change within 30 to 60 seconds. The fifth step is to compare the color to the chart, not by color-name but by color-position, because many reactions are dynamic: a color may change as a reaction proceeds, and the right color to compare against is the one the chart specifies at that time window. The sixth step is to repeat with a second reagent on a different sample from the same batch.

Photographing the reactions for later comparison or for upload to harm-reduction crowd-sourced services is a useful extension of the workflow. The reagent itself is the same, but the readout is much more useful in aggregate than in isolation.

What to Do With a Positive Result

A positive result on a reagent test (a color that does not match the chart for the substance the buyer believed they had) or a single line on a fentanyl test strip (indicating fentanyl detection) is a harm-reduction signal, not a judgment. The right response depends on what the result says. A sample that the buyer believed was MDMA but tested negative for MDMA and positive for a synthetic cathinone is a sample that the buyer should not consume. A sample that tested positive for fentanyl even at low concentrations is a sample that the buyer should not consume.

Several harm-reduction practices follow directly. Disposing of the sample safely, by taking it to a harm-reduction center or a local drug-take-back program, reduces the chance of accidental reuse. Not combining the substance with other substances, especially other substances that affect respiration or sedate the central nervous system, reduces the risk of overdose. Tells the seller's market that their supply is unsupervised, by sharing the result with harm-reduction crowd-sourced services, helps the buyer avoid the same result the next time. Ideally, the buyer would share the result with the seller; in practice, sellers are not always reachable.

If a buyer has used a substance before receiving a positive test result and begins to experience overdose symptoms (slow or stopped breathing, blue or gray lips or fingernails, inability to wake up, slowed or stopped heartbeat), the right response is to administer naloxone if available, call 911 or the local emergency number, and stay with the person until help arrives. Good Samaritan laws in many US states and most Canadian provinces protect both the caller and the person in medical distress from prosecution for drug possession in this scenario.

Limits and the Critics

Drug checking has real limits and a real set of critics, both of which are worth taking seriously. The limits are technical, practical, and legal. Each tool has blind spots. Reagent kits miss novel compounds. Fentanyl test strips miss non-fentanyl novel opioids. FTIR and Raman instruments cannot detect trace contaminants at concentrations below their detection thresholds. No single tool catches every contamination. The best practice is layered testing rather than a single-tool answer.

The critics, both inside and outside the harm-reduction community, argue that drug checking endorses use or makes use safer than it really is. The empirical evidence does not support this critique. A 2024 multi-site study published in Clinical Toxicology of 15 festival harm-reduction programs with on-site drug-checking services found that trained peer counselors successfully de-escalated the majority of psychological crises without medical intervention, and that having trained peers on site significantly reduced the rate of medical emergencies compared to events without such programs.

Drug checking is not an endorsement of use. It is a recognition that use is happening and a structured attempt to make it less bad. The distinction matters: drug checking is what public health calls a "structural intervention," meaning a change to the conditions in which use happens, rather than an "individual intervention" aimed at changing user behavior. Structural interventions include seat belts, naloxone distribution, syringe exchange, and drug checking. Individual interventions include anti-drug messaging, therapy, and peer-support networks. Both kinds of intervention matter, and the critique that drug checking endorses use conflates the structural layer with the individual one.

The honest read is that drug checking is one tool among many, not a substitute for any of them. It works best when paired with other structural interventions, harm-reduction programs, peer support, and clinical services for those experiencing complications. It is not a panacea, but it is one of the few harm-reduction interventions with consistent empirical support.

For more on how drug-checking and harm-reduction services work at music festivals, see our Festival Harm Reduction guide. For the broader context of how MDMA itself works in the body, see our MDMA explainer. For psilocybin's role and the risks that drug-checking addresses for street psilocybin, see our Psilocybin explainer.

This article is informational and does not constitute medical or legal advice. Drug checking is a harm-reduction practice, not an endorsement of use. It is designed to give buyers information about the substance they are about to use, not to encourage use or to make any use safe. Substance use carries real and well-documented risks.